Literature DB >> 31440812

Characteristics of patients with giant cell arteritis who experience visual symptoms.

Chung Shen Chean1, James A Prior2, Toby Helliwell1, John Belcher3, Sarah L Mackie4,5, Samantha L Hider1,6, Jennifer Liddle7, Christian D Mallen1.   

Abstract

Permanent vision loss is one of the most serious complications of giant cell arteritis (GCA) and therefore prompt diagnosis is paramount. However, diagnosis of GCA remains challenging due to its frequently non-specific presentation. Our aim was to identify differences in the characteristics of GCA patients with, and without, current visual symptoms. A cross-sectional survey was mailed to patients with a GCA Read code entered in their GP electronic medical record. Responders were categorised as those currently reporting a visual symptom or not. We compared general and GCA-specific characteristics in these two groups. The association of diagnostic delay with subsequent experience of visual symptoms was examined using unadjusted and adjusted linear regression analysis. 318 GCA patients responded to the survey (59.6%). Responders were predominantly female (69.8%), with a mean age of 73.7 years (SD 8.2). 28% reported current visual symptoms. There was no statistically significant difference in the general characteristics between those with and without visual symptoms. Of GCA-specific characteristics, pre-GCA diagnosis of diplopia (p = 0.018), temporary (p ≤ 0.001) or permanent visual problems (p = 0.001) and hoarseness (p = 0.004) were more common among those reporting current visual symptoms. There was no association between the extent of diagnostic delay and reporting of current visual symptoms. Though we found few characteristics to distinguish between GCA patients with or without current visual symptoms, diagnostic delay was not associated with current visual symptoms. Our findings highlighted the continued difficulty for clinicians to identify GCA patients at the highest risk of visual complications.

Entities:  

Keywords:  Diagnostic delay; Giant cell arteritis; Visual symptoms

Mesh:

Year:  2019        PMID: 31440812     DOI: 10.1007/s00296-019-04422-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  30 in total

1.  BSR and BHPR guidelines for the management of giant cell arteritis.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Leslie Alexander; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Pat James; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2010-04-05       Impact factor: 7.580

2.  Hoarse voice and visual loss.

Authors:  M N Ali; F C Figueiredo
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

3.  Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis.

Authors:  Carlo Salvarani; Luca Cimino; Pierluigi Macchioni; Dario Consonni; Fabrizio Cantini; Gianluigi Bajocchi; Nicolò Pipitone; Maria Grazia Catanoso; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2005-04-15

4.  Visual function and quality of life among patients with giant cell (temporal) arteritis.

Authors:  M J Kupersmith; R Speira; R Langer; M Richmond; M Peterson; H Speira; H Mitnick; S Paget
Journal:  J Neuroophthalmol       Date:  2001-12       Impact factor: 3.042

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients.

Authors:  E Liozon; F Herrmann; K Ly; P Y Robert; V Loustaud; P Soria; E Vidal
Journal:  Am J Med       Date:  2001-08-15       Impact factor: 4.965

7.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

8.  Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients.

Authors:  M A González-Gay; C García-Porrúa; J Llorca; A H Hajeer; F Brañas; A Dababneh; C González-Louzao; E Rodriguez-Gil; P Rodríguez-Ledo; W E Ollier
Journal:  Medicine (Baltimore)       Date:  2000-09       Impact factor: 1.889

9.  Content-based interpretation aids for health-related quality of life measures in clinical practice. An example for the visual function index (VF-14).

Authors:  J M Valderas; J Alonso; L Prieto; M Espallargues; X Castells
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

10.  High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.

Authors:  C T Berger; M Wolbers; P Meyer; T Daikeler; C Hess
Journal:  Rheumatology (Oxford)       Date:  2009-01-07       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.